Skip to main content
Article thumbnail
Location of Repository

Multiple Origins and Regional Dispersal of Resistant dhps in African Plasmodium falciparum Malaria

By Richard J. Pearce, Hirva Pota, Marie-Solange B. Evehe, El-Hadj Bâ, Ghyslain Mombo-Ngoma, Allen L. Malisa, Rosalynn Ord, Walter Inojosa, Alexandre Matondo, Diadier A. Diallo, Wilfred Mbacham, Ingrid V. van den Broek, Todd D. Swarthout, Asefaw Getachew, Seyoum Dejene, Martin P. Grobusch, Fanta Njie, Samuel Dunyo, Margaret Kweku, Seth Owusu-Agyei, Daniel Chandramohan, Maryline Bonnet, Jean-Paul Guthmann, Sian Clarke, Karen I. Barnes, Elizabeth Streat, Stark T. Katokele, Petrina Uusiku, Chris O. Agboghoroma, Olufunmilayo Y. Elegba, Badara Cissé, Ishraga E. A-Elbasit, Hayder A. Giha, S. Patrick Kachur, Caroline Lynch, John B. Rwakimari, Pascalina Chanda, Moonga Hawela, Brian Sharp, Inbarani Naidoo and Cally Roper


Cally Roper and colleagues analyze the distribution of sulfadoxine resistance mutations and flanking microsatellite loci to trace the emergence and dispersal of drug-resistant Plasmodium falciparum malaria in Africa

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1991). [Geographic approach to the epidemiology of chloroquine-resistance of Plasmodium falciparum in tropical Africa].
  2. (2005). A
  3. (2007). A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
  4. (2008). Adaptive copy number evolution in malaria parasites.
  5. (1998). Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria.
  6. (2003). Antifolate antimalarial resistance in southeast Africa: A population-based analysis.
  7. (2006). Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles.
  8. (2006). Artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: A clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
  9. (2001). Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 95:
  10. (2008). Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance,
  11. (2003). Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, south Sudan. Trans R Soc Trop Med Hyg 97: 229–235.
  12. (1997). Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa.
  13. (2003). DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxinepyrimethamine treatment efficacy.
  14. (2007). Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review.
  15. (2007). Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N’Zerekore.
  16. (2006). Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo.
  17. (2008). Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from Southwest Uganda.
  18. (2005). Epidemiology of drug-resistant malaria in Republic of Congo: Using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use.
  19. (1988). Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.
  20. (2004). Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan.
  21. (2002). Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum.
  22. (2004). Genetic markers of resistance to pyrimethamine and sulfonamides in Plasmodium falciparum parasites compared with the resistance patterns in isolates of Escherichia coli from the same children in Guinea-Bissau.
  23. (2008). High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area,
  24. (1996). High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 90:
  25. (2006). High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia.
  26. (2005). High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana.
  27. (2003). High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
  28. (1994). High resolution of human evolutionary trees with polymorphic microsatellites.
  29. (1998). In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment.
  30. (2004). Intercontinental spread of pyrimethamine-resistant malaria.
  31. (2007). Intermittent preventive therapy for malaria: progress and future directions.
  32. (2006). Invasion of Africa by a single pfcrt allele of South East Asian type.
  33. (1999). Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drugresistant Plasmodium falciparum strains.
  34. (1965). Migrants and Malaria.
  35. (2003). Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal province,
  36. (2003). Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania.
  37. (2002). Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.
  38. (2005). Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
  39. (1997). Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum.
  40. (1997). Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
  41. (2005). Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal.
  42. (2000). Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance.
  43. (1989). PHYLIP - Phylogeny Inference Package (Version 3.2).
  44. (2005). Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
  45. (2006). Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic.
  46. (2005). Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
  47. (2006). Prevalence of mutations associated with higher levels of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Car Nicobar Island and Assam,
  48. (2001). Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania.
  49. (1994). Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum.
  50. (2008). Probing the role of parasite-specific, distant structural regions on communication and catalysis in the bifunctional thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum.
  51. (1999). Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
  52. (2008). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.
  53. (2006). Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P.
  54. (2007). Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites.
  55. (2004). Relationship between age, molecular markers, and response to sulphadoxinepyrimethamine treatment in
  56. (1997). Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins.
  57. (1997). Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone.
  58. (1974). Sampling variances of heterozygosity and genetic distance.
  59. (2005). Selection strength and hitchhiking around two anti-malarial resistance genes.
  60. (1994). Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine.
  61. (2000). Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
  62. (2006). Short report: molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo.
  63. (2007). Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
  64. (2007). Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Cote d’Ivoire. Ann Trop Med Parasitol
  65. (1989). The History and Development of WHO Standard in vivo and in vitro Test Systems for the Sensitivity of Plasmodium falciparum and other Human Plasmodia to Antimalarial Drugs. London:
  66. (2007). Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in
  67. (2000). Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.
  68. (2007). World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.